Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-07-07
$70.61-0.44%
Close 2026-07-07 · 1-day change
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→NASDAQHealth CareBiotechnologySnapshot 2026-07-07
Reading TECH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track TECH free→QuarterlyIQ Insights · TECH
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $70.61. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $71 TECH trades at 38× p/e, in line with its 35× p/e peer median — but our blended $54 fair value sits below the price. It's a high-confidence read. Analysts target $49–$73. Even the durable-growth case — current growth held at sustainable margins — values it at about $68, at or below today's price, so you're paying beyond even the growth case. Not investment advice.
$49.00 – $73.00 (median $65.00) · 9 analysts · as of 2026-06-26
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $1.40/sh owner earnings.
Roughly priced in line with peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $65.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $26.20 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $26.53 | — | — | Hist. CAGR | high |
| graham number | 12M | $23.67 | — | — | TTM | high |
| Mgmt guidance | 12M | $14.84 | 35.3 | 0.42 | Mgmt | high |
| Peer EV/EBITDA | 12M | $31.13 | 15.5 | 2.01 | TTM | high |
| Peer P/FCF | 12M | $54.01 | 31.5 | 1.71 | TTM | high |
| Peer P/E | 12M | $66.41 | 35.3 | 1.88 | TTM | high |
| Peer P/S | 12M | $28.03 | 3.6 | 7.69 | TTM | high |
| PEG | 12M | $67.84 | 36.1 | 1.88 | TTM | high |
| residual income | 12M | $15.33 | — | — | TTM | high |
| Own P/E history | 12M | $70.61 | 37.6 | 1.88 | TTM | high |
| triangulated | 12M | $67.28 | 35.3 | 1.90 | Triangulated | high |
| Mgmt guidance | 3Y | $19.42 | 35.3 | 0.55 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $62.56 | 31.5 | 1.98 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $75.81 | 35.3 | 2.15 | Analyst | medium |
| Peer P/S | 3Y | $30.62 | 3.6 | 8.40 | Analyst | medium |
| PEG | 3Y | $77.45 | 36.1 | 2.15 | Analyst | medium |
| Own P/E history | 3Y | $80.60 | 37.6 | 2.15 | Analyst | medium |
| Mgmt guidance | 5Y | $23.23 | 35.3 | 0.66 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $69.01 | 31.5 | 2.19 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $82.89 | 35.3 | 2.35 | Analyst | high |
| Peer P/S | 5Y | $33.47 | 3.6 | 9.19 | Analyst | high |
| PEG | 5Y | $84.68 | 36.1 | 2.35 | Analyst | high |
| Own P/E history | 5Y | $88.13 | 37.6 | 2.35 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.